2025
SJR Q2
JCR Q3 · 2,1
137 matched articles
SCIE
Journal detail
Journal of Thrombosis and Thrombolysis
- Publisher
- Springer
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
092953051573742X
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,65
- Quartile Q2
- H-Index 86
- Cites/doc 2,09
- Docs (3y) 513
- Cites (3y) 1.062
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,1
- 5Y JIF 2
- JCI 0,54
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Cardiology and Cardiovascular Medicine Q2
- Hematology Q2
Areas
- Medicine
WoS categories
- Cardiac & Cardiovascular System | Hematology | Peripheral Vascular Diseases
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,65 | 2,1 | 2 | 0,54 | Q2 | 86 |
| 2024 | Q2 | Q2 | 0,736 | 2,2 | 2,2 | 0,58 | Q2 | 83 |
| 2023 | Q2 | Q2 | 0,744 | 2,3 | 2,5 | 0,83 | Q2 | 83 |
| 2022 | Q2 | Q2 | 0,862 | 4 | 3,2 | 0,84 | Q1 | 83 |
| 2021 | Q1 | Q2 | 0,974 | 5,2 | 4,2 | 0,88 | Q1 | 83 |
| 2020 | Q2 | Q3 | 0,708 | 2,3 | 2,7 | 0,53 | Q2 | 83 |
| 2019 | Q2 | Q3 | 0,838 | 2,1 | 2,1 | 0,69 | Q2 | 83 |
| 2018 | — | Q2 | — | 2,9 | 2,2 | 0,75 | Q2 | — |
| 2017 | Q2 | Q2 | 0,991 | 2,6 | 2 | 0,72 | Q2 | 83 |
| 2016 | Q2 | Q3 | 0,824 | 2,1 | 2,1 | — | — | 83 |
| 2015 | Q2 | Q3 | 0,804 | 1,9 | 1,9 | — | — | 83 |
| 2014 | Q2 | Q3 | 0,886 | 2,2 | 1,8 | — | — | 83 |
| 2013 | Q2 | Q3 | 0,824 | 2 | 1,6 | — | — | 83 |
| 2012 | Q2 | Q3 | 0,781 | 2 | 1,7 | — | — | 83 |
| 2011 | Q2 | Q3 | 0,636 | 1,5 | 1,6 | — | — | 83 |
| 2010 | Q2 | Q3 | 0,698 | 1,5 | 1,7 | — | — | 83 |
| 2009 | — | Q3 | — | 1,8 | 1,9 | — | — | — |
| 2008 | — | Q3 | — | 2,3 | 1,9 | — | — | — |
| 2007 | — | Q3 | — | 1,4 | 1,5 | — | — | — |
| 2006 | — | Q3 | — | 1,2 | — | — | — | — |
| 2005 | — | Q4 | — | 1,1 | — | — | — | — |
| 2004 | — | Q4 | — | 0,9 | — | — | — | — |
| 2003 | — | Q3 | — | 1,1 | — | — | — | — |
| 2002 | — | Q3 | — | 1,1 | — | — | — | — |
| 2001 | — | Q3 | — | 1,1 | — | — | — | — |
| 2000 | — | Q3 | — | 0,8 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q3 | 138/237 |
| 2025 | HEMATOLOGY | SCIE | Q3 | Q2 | 61/103 |
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 57/100 |
| 2024 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 111/231 |
| 2024 | HEMATOLOGY | SCIE | Q3 | Q2 | 51/99 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 50/98 |
| 2023 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 104/222 |
| 2023 | HEMATOLOGY | SCIE | Q2 | Q2 | 48/97 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 44/96 |
| 2022 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 53/143 |
| 2022 | HEMATOLOGY | SCIE | Q2 | Q2 | 28/79 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 26/68 |
| 2021 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 47/143 |
| 2021 | HEMATOLOGY | SCIE | Q2 | Q2 | 30/78 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 20/67 |
| 2020 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 93/142 |
| 2020 | HEMATOLOGY | SCIE | Q4 | Q3 | 59/76 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 48/65 |
| 2019 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q3 | Q2 | 83/138 |
| 2019 | HEMATOLOGY | SCIE | Q3 | Q2 | 56/76 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 44/65 |
| 2018 | CARDIAC & CARDIOVASCULAR SYSTEMS | SCIE | Q2 | Q2 | 56/136 |
| 2018 | HEMATOLOGY | SCIE | Q2 | Q2 | 35/73 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 26/65 |
| 2017 | HEMATOLOGY | SCIE | Q2 | Q2 | 35/71 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 34/65 |
| 2016 | HEMATOLOGY | SCIE | Q3 | — | 42/70 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 43/63 |
| 2015 | HEMATOLOGY | SCIE | Q3 | — | 50/70 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 44/63 |
| 2014 | HEMATOLOGY | SCIE | Q3 | — | 44/68 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 40/60 |
| 2013 | HEMATOLOGY | SCIE | Q3 | — | 45/68 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 41/65 |
| 2012 | HEMATOLOGY | SCIE | Q3 | — | 44/67 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 39/68 |
| 2011 | HEMATOLOGY | SCIE | Q3 | — | 50/68 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 48/68 |
| 2010 | HEMATOLOGY | SCIE | Q3 | — | 49/66 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 43/68 |
| 2009 | HEMATOLOGY | SCIE | Q3 | — | 42/61 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 33/61 |
| 2008 | HEMATOLOGY | SCIE | Q3 | — | 38/62 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 29/56 |
| 2007 | HEMATOLOGY | SCIE | Q3 | — | 46/63 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/54 |
| 2006 | HEMATOLOGY | SCIE | Q4 | — | 52/61 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 36/52 |
| 2005 | HEMATOLOGY | SCIE | Q4 | — | 51/60 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 39/51 |
| 2004 | HEMATOLOGY | SCIE | Q4 | — | 50/62 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 43/51 |
| 2003 | HEMATOLOGY | SCIE | Q4 | — | 48/62 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 34/52 |
| 2002 | HEMATOLOGY | SCIE | Q4 | — | 49/61 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 33/52 |
| 2001 | HEMATOLOGY | SCIE | Q3 | — | 42/59 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 35/50 |
| 2000 | HEMATOLOGY | SCIE | Q4 | — | 47/60 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 33/45 |